AU2019404924B2 - O-linked glycosylation recognition motifs - Google Patents

O-linked glycosylation recognition motifs

Info

Publication number
AU2019404924B2
AU2019404924B2 AU2019404924A AU2019404924A AU2019404924B2 AU 2019404924 B2 AU2019404924 B2 AU 2019404924B2 AU 2019404924 A AU2019404924 A AU 2019404924A AU 2019404924 A AU2019404924 A AU 2019404924A AU 2019404924 B2 AU2019404924 B2 AU 2019404924B2
Authority
AU
Australia
Prior art keywords
seq
comp
protein
epa
glycosylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019404924A
Other languages
English (en)
Other versions
AU2019404924A1 (en
Inventor
Christian HARDING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaxnewmo LLC
Original Assignee
Vaxnewmo LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxnewmo LLC filed Critical Vaxnewmo LLC
Publication of AU2019404924A1 publication Critical patent/AU2019404924A1/en
Application granted granted Critical
Publication of AU2019404924B2 publication Critical patent/AU2019404924B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2019404924A 2018-12-21 2019-11-05 O-linked glycosylation recognition motifs Active AU2019404924B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862783971P 2018-12-21 2018-12-21
US62/783,971 2018-12-21
PCT/US2019/059893 WO2020131236A1 (en) 2018-12-21 2019-11-05 O-linked glycosylation recognition motifs

Publications (2)

Publication Number Publication Date
AU2019404924A1 AU2019404924A1 (en) 2021-07-08
AU2019404924B2 true AU2019404924B2 (en) 2025-09-18

Family

ID=71101542

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019404924A Active AU2019404924B2 (en) 2018-12-21 2019-11-05 O-linked glycosylation recognition motifs

Country Status (7)

Country Link
US (1) US12350342B2 (enExample)
EP (1) EP3897685B1 (enExample)
JP (2) JP7699543B2 (enExample)
AU (1) AU2019404924B2 (enExample)
CA (1) CA3124312A1 (enExample)
ES (1) ES3055827T3 (enExample)
WO (1) WO2020131236A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3039659T3 (en) 2015-02-26 2025-10-23 Vaxnewmo Llc Acinetobacter o-oligosaccharyltransferases and uses thereof
JP2021528059A (ja) 2018-06-16 2021-10-21 ヴァックスニューモ エルエルシーＶａｘｎｅｗｍｏ Ｌｌｃ グリコシル化されたＣｏｍＰピリンバリアント、製造方法及びその使用
US12350342B2 (en) 2018-12-21 2025-07-08 Vaxnewmo Llc O-linked glycosylation recognition motifs
US20240066109A1 (en) * 2020-12-31 2024-02-29 Vaxnewmo Llc Klebsiella Pneumoniae O-Antigen Glycosylated Proteins and Methods of Making and Uses Thereof
EP4329796A4 (en) * 2021-04-28 2025-03-19 Vaxnewmo Llc Minimal sequons sufficient for o-linking glycosylation
CN115120712B (zh) * 2022-06-30 2025-11-18 中国人民解放军军事科学院军事医学研究院 肺炎链球菌糖蛋白生物结合疫苗及其制备方法和应用
WO2024077205A2 (en) * 2022-10-07 2024-04-11 Vaxnewmo Llc Moraxellaceae o-linking oligosaccharyltransferases, glycosylation fragments, and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016134485A1 (en) * 2015-02-26 2016-09-01 Vaxalta Inc. Acinetobacter o-oligosaccharyltransferases and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
CA2671709C (en) 2006-12-13 2016-08-16 The Governors Of The University Of Alberta Methods and systems for o-glycosylating proteins
US20130196410A1 (en) * 2010-03-05 2013-08-01 Alnylam Pharmaceuticals, Inc Compositions and methods for modifying the glycosylation pattern of a polypeptide
CA2844831A1 (en) 2011-08-12 2013-02-21 The Governors Of The University Of Alberta Method of diagnosing bacterial infections using bacterial glycoproteins
WO2013067523A1 (en) 2011-11-04 2013-05-10 Cornell University A prokaryote-based cell-free system for the synthesis of glycoproteins
ES2905107T3 (es) 2012-10-12 2022-04-07 Glaxosmithkline Biologicals Sa Procedimientos de modificación de células hospedadoras
EP3508579B1 (en) 2012-11-07 2021-06-30 GlaxoSmithKline Biologicals SA Production of recombinant vaccine in e. coli by enzymatic conjugation
US9499614B2 (en) * 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
JP6356229B2 (ja) 2013-06-04 2018-07-11 アイコン ジェネティクス ゲーエムベーハー 植物産生糖タンパク質及び組換え糖タンパク質のｎ−グリコシル化部位占有率を調節する方法
US9988426B2 (en) 2014-09-18 2018-06-05 University Of Maryland, Baltimore Broad spectrum conjugate vaccine to prevent Klebsiella pneumoniae and Pseudomonas aeruginosa infections
CN107614679B (zh) * 2014-12-30 2026-04-07 葛兰素史密丝克莱恩生物有限公司 用于蛋白糖基化的组合物和方法
WO2018135860A1 (ko) * 2017-01-17 2018-07-26 포항공과대학교 산학협력단 식물 세포에서의 목적 단백질 발현을 위한 재조합 벡터
EP3492481A1 (en) 2017-11-30 2019-06-05 Vaxxilon AG Vaccine against klebsiella pneumoniae
JP2021528059A (ja) 2018-06-16 2021-10-21 ヴァックスニューモ エルエルシーＶａｘｎｅｗｍｏ Ｌｌｃ グリコシル化されたＣｏｍＰピリンバリアント、製造方法及びその使用
CN113227125A (zh) 2018-12-12 2021-08-06 葛兰素史密丝克莱恩生物有限公司 用于o-连接的糖基化的修饰的载体蛋白
US12350342B2 (en) 2018-12-21 2025-07-08 Vaxnewmo Llc O-linked glycosylation recognition motifs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016134485A1 (en) * 2015-02-26 2016-09-01 Vaxalta Inc. Acinetobacter o-oligosaccharyltransferases and uses thereof

Also Published As

Publication number Publication date
JP2025032259A (ja) 2025-03-11
JP2022514704A (ja) 2022-02-14
EP3897685B1 (en) 2025-10-08
AU2019404924A1 (en) 2021-07-08
EP3897685A1 (en) 2021-10-27
JP7699543B2 (ja) 2025-06-27
US12350342B2 (en) 2025-07-08
ES3055827T3 (en) 2026-02-16
CA3124312A1 (en) 2020-06-25
EP3897685A4 (en) 2022-07-27
WO2020131236A1 (en) 2020-06-25
US20220088211A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
AU2019404924B2 (en) O-linked glycosylation recognition motifs
US12577280B2 (en) Glycosylated comp pilin variants, methods of making and uses thereof
JP7551618B2 (ja) Ｏ－結合型グリコシル化のための修飾キャリアタンパク質
JP2023531242A (ja) 改変Ｅｘｏｔｏｘｉｎ Ａタンパク質
US20240066109A1 (en) Klebsiella Pneumoniae O-Antigen Glycosylated Proteins and Methods of Making and Uses Thereof
WO2021013854A1 (en) Quantification of bioconjugate glycosylation
US20240207383A1 (en) Minimal Sequons Sufficient for O-Linking Glycosylation
WO2024077205A2 (en) Moraxellaceae o-linking oligosaccharyltransferases, glycosylation fragments, and uses thereof
CN120897997A (zh) 用于生产具有与第二多肽配偶体的异肽键的糖缀合物多肽的组合物和方法以及这些糖缀合物多肽的用途
Mayer et al. A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)